Concept of mapping

Drug Information Journal

Volumn 30, Issue 4, 1996, Pages 1085-1089

  Shah, Vinod P ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Critical manufacturing variables; Dissolution; Mapping; Response surface

Indexed keywords

CELLULOSE; DODECYL SULFATE SODIUM; LUBRICATING AGENT; MAGNESIUM STEARATE; METOPROLOL; PIROXICAM; POVIDONE; PROPRANOLOL;

AREA UNDER THE CURVE; BIOEQUIVALENCE; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DEVELOPMENT; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG RELEASE; DRUG SOLUBILITY; EQUIPMENT; FOOD AND DRUG ADMINISTRATION; MATHEMATICAL MODEL; PARTICLE SIZE; PHARMACEUTICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; TABLET;

EID: 0029836972     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159603000425     Document Type: Review

References (6)

1. Skelly JP, et. al. In vitro and in vivo testing and correlation for oral controlled/modified release dosage forms. Pharm Res. 1990;7:975-982.
2. Shah VP, et. al. Scale-up of controlled release products - preleminary considerations. Pharm Technol. 1992;16(5):35-40.
3. Skelly JP, et. al. Workshop Report: Scale-up of Oral Extended-release dosage forms. Pharm Res. 1993;10: 1800-1805.
4. FDA Contract, 223-91-3401 at University of Maryland, Baltimore, Principle investigator: Larry Augsberger.
5. Siewert M. FIP Guidelines for dissolution testing of solid oral products. Pharm Ind. 1995;57:362-369.
6. Meyer MC, et. al. The bioequivalence of carbamazepine tablets with a history of clinical failures. Pharm Res. 1992;9:1612-1616.